In studies of RA patients, IL-25 was found to inhibit the pro-inflammatory effects of IL-17 A by competing for binding to the IL-17RA receptor, but could also inhibit osteoclastogenesis through STAT3 and p38MAPK pathways in RA [11, 59]. Here, IL25 is linked to rheumatoid arthritis.